Stanford, California 94305

  • We Will Focus on Assessing the Clinical Performance of the BiliCare Device


The primary objective of this study is to define the performance evaluation of BiliCare TcB device to the "gold standard" bilirubin tests.

Study summary:

Neonatal hyperbilirubinemia or newborn jaundice impacts over 85% of all newborns [1]. Regardless of the mechanism, excessive hyperbilirubinemia has been traditionally treated with phototherapy to minimize any probable risk of developing bilirubin-induced neurotoxicity. However, earlier and more recent data suggest that pre-discharge bilirubin screening for risk of significant hyperbilirubinemia, whether due to a rapid bilirubin production or an earlier age of onset, has impacted the guidelines for clinical use of phototherapy [1, 2]. In this study, we plan to test the performance of a novel transcutaneous device (BiliCareTM) first for screening for bilirubin levels at postnatal age of 6 to 48 hrs; and possibly also, to substitute the use of this measurement for total plasma/serum bilirubin (TB). This device applies a novel light transmission technology that has the potential to measure bilirubin as a point-of-care test in the subcutaneous tissue, and then uses an internal algorithm to calculate bilirubin levels in the skin. In this proposalstudy, we will to assess the clinical performance of the BiliCare by correlating measurements made by this device to near-concurrent measure of total plasma/serum bilirubin at normative ranges (mean, median, range and inter-quartile ranges ) for all term and late-preterm newborns (including those who are at-risk for jaundice and / or being administered with phototherapy) born to families of diverse race and ethnic backgrounds.


Inclusion Criteria: - Parental informed consent - Male and female newborns with a GA ≥ 35 wks - Enrollment at age > 6 hrs until neonatal discharge. - Pre-phototherapy Exclusion Criteria: - Infants requiring respiratory assistance (such as mechanical ventilation) - Severe or life-threatening congenital anomalies - Hematomas at the point of measurement on both ears - Neonates undergone blood transfusion



Primary Contact:

Principal Investigator
Vinney Bhutani, MD
Stanford Medical Center

Martin Cuardado, Coordinator
Phone: 415 531 8778

Backup Contact:

Eyal Gerber, Sponser
Phone: +972-524873130

Location Contact:

Stanford, California 94305
United States

Vinod Bhutani, MD
Phone: 650-723-5711

Site Status: Recruiting

Data Source:

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.